You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CMR (Complete Molecular Remission)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Chronic Leukemia Trial in France (Additional biological samples)

Active, not recruiting
  • Chronic Leukemia
  • Additional biological samples
  • Besançon, France
  • +3 more
May 31, 2022

Chronic Phase Chronic Myeloid Leukemia Trial in Worldwide (Dasatinib)

Completed
Has Results
  • Chronic Phase Chronic Myeloid Leukemia
  • Duarte, California
  • +27 more
Dec 7, 2021

Leukemia, Chronic Myeloid Trial in Ann Arbor, Winston-Salem (Nilotinib, Ruxolitinib)

Withdrawn
  • Leukemia, Chronic Myeloid
  • Ann Arbor, Michigan
  • +1 more
Feb 11, 2021

Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, ph+ Acute Lymphoblastic Leukemia Trial in Chicago (Inotuzumab ozogamicin,

Recruiting
  • Lymphoblastic Leukemia
  • +2 more
  • Inotuzumab ozogamicin
  • +7 more
  • Chicago, Illinois
    University of Chicago Medical Center
May 16, 2022

Acute Lymphoblastic Leukemia, Adult, Ph+ ALL, Newly Diagnosed Trial in Czechia (Ponatinib 15 MG Oral Tablet)

Active, not recruiting
  • Acute Lymphoblastic Leukemia, Adult
  • +2 more
  • Ponatinib 15 MG Oral Tablet
  • Brno, Czechia
  • +6 more
Nov 30, 2022

Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Trial in Tianjin (Olverembatinib, Venetoclax, prednisone)

Recruiting
  • Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
  • Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Oct 21, 2022

Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia Trial in Xi'an (Olverembatinib plus venetoclax and dexamethasone)

Recruiting
  • Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
  • Olverembatinib plus venetoclax and dexamethasone
  • Xi'an, Shannxi, China
    Department of Hematology, Xijing Hospital, Fourth Military Medic
Oct 9, 2023

Core Binding Factor Acute Myeloid Leukemia Trial in Guangzhou (Sorafenib, Idarubicin, Cytarabine)

Recruiting
  • Core Binding Factor Acute Myeloid Leukemia
  • Guangzhou, Guangdong, China
    Department of Hematology,Nanfang Hospital, Southern Medical Univ
May 31, 2022

Complete Molecular Remission After Stopping Imatinib Chronic

Completed
  • Chronic Myeloid Leukemia
  • Interruption of the treatment by Imatinib
  • Angers, France
  • +18 more
Jun 18, 2020

Acute Lymphoblastic Leukemia Trial in Ann Arbor (Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Nov 28, 2022

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Trial in France (Nilotinib)

Completed
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive
  • Angers, France
  • +9 more
Aug 17, 2022

Chronic Myeloid Leukemia Trial in Worldwide (Stopping treatment with TKI)

Completed
  • Chronic Myeloid Leukemia
  • Stopping treatment with TKI
  • Brno, Czechia
  • +49 more
Oct 29, 2021

Acute Lymphoblastic Leukemia Trial in New York (Ruxolitinib, Dasatinib, Dexamethasone)

Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Jul 25, 2022

Philadelphia-Positive ALL Trial in Suzhou (Olverembatinib combined with chemo)

Not yet recruiting
  • Philadelphia-Positive ALL
  • Olverembatinib combined with chemotherapy
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University, Jiangsu Ins
Jul 17, 2022

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, BCR-ABL1 Fusion Protein

Recruiting
  • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +7 more
  • Blinatumomab
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 31, 2022

Amyloidosis, Primary, Cardiomyopathy Trial in Boston (F-18 florbetapir/C-11 acetate PET, MRI, N-13 ammonia PET)

Recruiting
  • Amyloidosis, Primary
  • Cardiomyopathy
  • F-18 florbetapir/C-11 acetate PET
  • +2 more
  • Boston, Massachusetts
    Brigham and Womens' Hospital
Oct 23, 2022

Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive Trial in New York (Blinatumomab, dasatinib, dexamethasone)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Philadelphia Chromosome-Positive
  • Blinatumomab
  • +3 more
  • New York, New York
  • +1 more
Nov 10, 2022

Philadelphia Chromosome, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia Trial in Suzhou (Azacitidine, Venetoclax,

Recruiting
  • Philadelphia Chromosome
  • +4 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Jun 23, 2022

Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, BCR/ABL-Positive, in Remission, Chronic Myeloid Leukemia in Remission Trial

Recruiting
  • Chronic Myeloid Leukemia
  • +2 more
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
  • Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
  • Houston, Texas
  • +3 more
Jan 25, 2022

B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Recurrent B Acute

Recruiting
  • B Acute Lymphoblastic Leukemia
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
Dec 16, 2022

Relapsed/Refractory Philadelphia Positive B-precursor ALL Trial in Worldwide (Blinatumomab)

Completed
Has Results
  • Relapsed/Refractory Philadelphia Positive B-precursor ALL
  • Duarte, California
  • +21 more
Sep 8, 2022

Acute Promyelocytic Leukemia, Induction Therapy, Oral Trial in Beijing (Etoposide, Daunorubicin)

Recruiting
  • Acute Promyelocytic Leukemia
  • +2 more
  • Beijing, Beijing, China
    Peking University Institute of Hematology
Apr 26, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Philadelphia-Positive ALL, Acute Lymphoblastic Leukemia, in Relapse Trial in Italy (Ponatinib)

Recruiting
  • Philadelphia-Positive ALL
  • Acute Lymphoblastic Leukemia, in Relapse
  • Ancona, Italy
  • +21 more
Jan 3, 2022

RWE of 1st Line Treatment With ATO/ATRA for Adult APL

Recruiting
  • Promyelocytic Leukemia, Adult Acute
  • Evaluation of first line treatment with ATO/ATRA outcome
  • Caba, Argentina
  • +1 more
Nov 9, 2021